PM&R
Volume 2, Issue 1 , Pages 37-42 , January 2010

Pharmacokinetics of Amantadine in Children With Impaired Consciousness due to Acquired Brain Injury: Preliminary Findings Using a Sparse-sampling Technique

Portions of the material in this manuscript were previously presented at the Annual Assembly of the AAPM&R in Philadelphia, 2005.

  • Jilda N. Vargus-Adams, MD, MSc

      Affiliations

    • Departments of Physical Medicine & Rehabilitation and Pediatrics, Center for Epidemiology and Biostatistics and Division of Pediatric Rehabilitation, MLC 4009, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229-3039; University of Cincinnati School of Medicine, Cincinnati, OH†
    • Corresponding Author InformationAddress correspondence to: J.N.V.-A.
    • ,
  • Mary A. McMahon, MD

      Affiliations

    • Division of Pediatric Rehabilitation, Departments of Physical Medicine & Rehabilitation and Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Cincinnati, OH‡
    • ,
  • Linda J. Michaud, MD

      Affiliations

    • Division of Pediatric Rehabilitation, Departments of Physical Medicine & Rehabilitation and Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Cincinnati, OH§
    • ,
  • Judy Bean, PhD

      Affiliations

    • Department of Pediatrics, Center for Epidemiology and Biostatistics, Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Cincinnati, OH
    • ,
  • Alexander A. Vinks, PharmD, PhD

      Affiliations

    • Department of Pediatrics, Division of Clinical Pharmacology and Pediatric Pharmacology Research Unit, University of Cincinnati School of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Cincinnati School of Medicine, Cincinnati, OH∥

Received 13 May 2009 ,Accepted 26 October 2009.

References 

  1. Schneider WN, Drew-Cates J, Wong TM, Dombovy ML. Cognitive and behavioural efficacy of amantadine in acute traumatic brain injury: An initial double-blind placebo-controlled study. Brain Inj. 1999;13:863–872
  2. Green LB, Hornyak JE, Hurvitz EA. Amantadine in pediatric patients with traumatic brain injury: A retrospective, case-controlled study. Am J Phys Med Rehabil. 2004;83:893–897
  3. Patrick PD, Blackman JA, Mabry JL, Buck ML, Gurka MJ, Conaway MR. Dopamine agonist therapy in low-response children following traumatic brain injury. J Child Neurol. 2006;21:879–885
  4. Patrick PD, Buck ML, Conaway MR, Blackman JA. The use of dopamine enhancing medications with children in low response states following brain injury. Brain Inj. 2003;17:497–506
  5. Williams SE. Amantadine treatment following traumatic brain injury in children. Brain Inj. 2007;21:885–889
  6. Gianutsos G, Chute S, Dunn JP. Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine. Eur J Pharmacol. 1985;110:357–361
  7. Bleidner WE, Harmon JB, Hewes WE, Lynes TE, Hermann EC. Absorption, distribution and excretion of amantadine hydrochloride. J Pharmacol Exp Ther. 1965;150:484–490
  8. Aoki FY, Sitar DS, Ogilvie RI. Amantadine kinetics in healthy young subjects after long-term dosing. Clin Pharmacol Ther. 1979;26:729–736
  9. Aoki FY. Amantadine kinetics in healthy elderly men: Implications for influenza prevention. Clin Pharmacol Ther. 1985;37:137–144
  10. Munson P. Drug Treatment of Movement Disorders. New York: Chapman & Hall; 1995;
  11. Aoki FY. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet. 1988;14:35–51
  12. Physicians' Desk Reference. 54th ed.. Montvale, NJ: Medical Economics Company Inc; 2000;
  13. Gualtieri T, Chandler M, Coons TB, Brown LT. Amantadine: A new clinical profile for traumatic brain injury. Clin Neuropharmacol. 1989;12:258–270
  14. Shields WD, Lake JL, Chugani HT. Amantadine in the treatment of refractory epilepsy in childhood: An open trial in 10 patients. Neurology. 1985;35:579–581
  15. Cowell L. Amantadine: A potential adjuvant therapy following traumatic brain injury. J Head Trauma Rehabil. 1995;10:91–94
  16. Jostpille R. The use of amantadine after pediatric traumatic brain injury. [abstract] Arch Phys Med Rehabil. 1998;79:1176
  17. Zafonte RD, Watanabe T, Mann NR. Amantadine: A potential treatment for the minimally conscious state. Brain Inj. 1998;12:617–621
  18. McMahon MA, Vargus-Adams JN, Michaud LJ, Bean J. Effects of amantadine in children with impaired consciousness caused by acquired brain injury: A pilot study. Am J Phys Med Rehabil. 2009;88:525–532
  19. D'Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm. 1981;9:739–756
  20. Vinks AA, Mouton JW, Touw DJ, Heijerman HG, Danhof M, Bakker W. Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy. Antimicrob Agents Chemother. 1996;40:1091–1097
  21. Suckow RF, Zhang MF, Collins ED, Fischman MW, Cooper TB. Sensitive and selective liquid chromatographic assay of memantine in plasma with fluorescence detection after pre-column derivatization. J Chromatogr B Biomed Sci Appl. 1999;729:217–224
  22. Proost J. Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Computer Biol Med. 1992;22:155–163

 This CME activity is designated for 1.0 AMA PRA Category 1 Credit™ and can be completed online at me.aapmr.org. Log on to www.me.aapmr.org, go to Lifelong Learning (CME) and select Journal-based CME from the drop down menu. This activity is FREE to AAPM&R members and $25 for non-members.

 Disclosure Key can be found on the Table of Contents and at www.pmrjournal.org

PII: S1934-1482(09)01500-7

doi: 10.1016/j.pmrj.2009.10.010

PM&R
Volume 2, Issue 1 , Pages 37-42 , January 2010

Article Tools

* Image Usage & Resolution